{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:25:31Z","timestamp":1785551131243,"version":"3.56.0"},"reference-count":35,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:00Z","timestamp":1712880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Treating psoriasis patients requires the consideration of potential underlying complications like latent viral infections and chronic kidney disease, which may influence therapy selection. Case presentation: A patient with end-stage kidney disease (ESKD) undergoing hemodialysis (HD) was successfully treated with bimekizumab, an IgG1 humanized monoclonal antibody inhibiting interleukin (IL)-17A and IL-17F. This case appears to be the first documented instance of effective anti-IL-17A\/IL-17F antibody treatment in a psoriasis patient undergoing HD, with a sustained positive response for eight months. Discussion: Studies indicate the comparable pharmacokinetics, efficacy, and safety of certain psoriasis drugs in patients with chronic kidney disease (CKD) and those with normal renal function. The positive clinical outcome observed following treatment with bimekizumab aligns with the existing literature on this topic. However, further studies are needed to objectively evaluate the pharmacokinetics, efficacy, and safety of this drug in this specific setting. Conclusions: This documented case represents the first known use of bimekizumab to treat psoriasis in patients undergoing dialysis, suggesting its potential effectiveness and safety in this population.<\/jats:p>","DOI":"10.3390\/jcm13082250","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T09:28:06Z","timestamp":1712914086000},"page":"2250","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Successful Treatment with Bimekizumab of a Psoriatic Patient Undergoing Hemodialysis: A Case Report and Review of the Literature"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6295-3574","authenticated-orcid":false,"given":"Nicoletta","family":"Bernardini","sequence":"first","affiliation":[{"name":"Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit \u201cDaniele Innocenzi\u201d, \u201cSapienza\u201d University of Rome, Polo Pontino, 04100 Latina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6312-7709","authenticated-orcid":false,"given":"Luca","family":"Ambrosio","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Clinical Internal Anesthesiologic Cardiovascular Sciences, \u201cSapienza\u201d University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ersilia","family":"Tolino","sequence":"additional","affiliation":[{"name":"Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit \u201cDaniele Innocenzi\u201d, \u201cSapienza\u201d University of Rome, Polo Pontino, 04100 Latina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3795-3190","authenticated-orcid":false,"given":"Ilaria","family":"Proietti","sequence":"additional","affiliation":[{"name":"Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit \u201cDaniele Innocenzi\u201d, \u201cSapienza\u201d University of Rome, Polo Pontino, 04100 Latina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4478-5404","authenticated-orcid":false,"given":"Nevena","family":"Skroza","sequence":"additional","affiliation":[{"name":"Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit \u201cDaniele Innocenzi\u201d, \u201cSapienza\u201d University of Rome, Polo Pontino, 04100 Latina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Potenza","sequence":"additional","affiliation":[{"name":"Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit \u201cDaniele Innocenzi\u201d, \u201cSapienza\u201d University of Rome, Polo Pontino, 04100 Latina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Rendon, A., and Sch\u00e4kel, K. (2019). Psoriasis Pathogenesis and Treatment. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061475"},{"key":"ref_3","first-page":"CD011535","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: A network meta-analysis","volume":"2022","author":"Sbidian","year":"2022","journal-title":"Emergencias"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","article-title":"The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in Plaque Psoriasis\u2014Results of Two Phase 3 Trials","volume":"371","author":"Langley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.jaci.2016.06.038","article-title":"\u03b2-Defensin 2 is a responsive biomarker of IL-17A\u2013driven skin pathology in patients with psoriasis","volume":"139","author":"Kolbinger","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1136\/annrheumdis-2017-212127","article-title":"Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: Evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation","volume":"77","author":"Glatt","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2199106","DOI":"10.1080\/09546634.2023.2199106","article-title":"Efficacy and safety of bimekizumab for the treatment of psoriasis: A systematic review and meta-analysis of randomized clinical trials","volume":"34","author":"Qiu","year":"2023","journal-title":"J. Dermatol. Treat."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0140-6736(22)02302-9","article-title":"Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: A randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)","volume":"401","author":"McInnes","year":"2023","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0140-6736(22)02303-0","article-title":"Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-\u03b1 inhibitors: A randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)","volume":"401","author":"Merola","year":"2023","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1136\/ard-2022-223595","article-title":"Efficacy and safety of bimekizumab in axial spondyloarthritis: Results of two parallel phase 3 randomised controlled trials","volume":"82","author":"Deodhar","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1001\/jamadermatol.2021.2905","article-title":"Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial","volume":"157","author":"Glatt","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1177\/10600280231170031","article-title":"Choosing Systemic Agents for Psoriasis","volume":"58","author":"Kontzias","year":"2024","journal-title":"Ann. Pharmacother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1211\/jpp.57.11.0005","article-title":"The pharmacokinetics of etanercept in patients with end-stage renal disease on haemodialysis","volume":"57","author":"Don","year":"2010","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"E26","DOI":"10.1111\/1346-8138.15132","article-title":"Successful treatment with secukinumab of three psoriatic patients undergoing dialysis","volume":"47","author":"Mukai","year":"2020","journal-title":"J. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jdcr.2018.11.016","article-title":"An interleukin-17 inhibitor successfully treated a complicated psoriasis and psoriatic arthritis patient with hepatitis B virus infection and end-stage kidney disease on hemodialysis","volume":"5","author":"Koike","year":"2019","journal-title":"JAAD Case Rep."},{"key":"ref_19","first-page":"3863152","article-title":"A Case of Psoriasis Vulgaris Treated with Brodalumab in a Hemodialysis Patient with End-Stage Renal Disease due to Diabetic Nephropathy","volume":"2020","author":"Ishibashi","year":"2020","journal-title":"Case Rep. Dermatol. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1684\/ejd.2017.3064","article-title":"Efficacy of biologics in psoriasis patients under hemodialysis","volume":"27","author":"Larquey","year":"2017","journal-title":"Eur. J. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/j.1468-3083.2006.01636.x","article-title":"Psoriasis under haemodialysis","volume":"20","author":"Yamamoto","year":"2006","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/1346-8138.14531","article-title":"Increased risk of incident psoriasis in end-stage renal disease patients on chronic hemodialysis: A nationwide population-based cohort study","volume":"45","author":"Wang","year":"2018","journal-title":"J. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Wild, J., Keller, K., Karbach, S., Weinmann-Menke, J., M\u00fcnzel, T., and Hobohm, L. (2022). Case-Fatality and Temporal Trends in Patients with Psoriasis and End-Stage Renal Disease. J. Clin. Med., 11.","DOI":"10.3390\/jcm11154328"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1016\/j.transproceed.2013.08.005","article-title":"Complete Clinical Remission of Psoriasis 6 Months After Renal Transplantation","volume":"45","author":"Mele","year":"2013","journal-title":"Transplant. Proc."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.amjms.2021.03.009","article-title":"Treatment of psoriasis in end-stage renal disease patients is associated with decreased mortality: A retro-spective cohort study","volume":"362","author":"Schwade","year":"2021","journal-title":"Am. J. Med. Sci."},{"key":"ref_26","first-page":"e299","article-title":"Efficacy and safety of ustekinumab in a patient with chronic renal failure on hemodialysis","volume":"53","author":"Bustos","year":"2014","journal-title":"Int. J. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/j.1365-4632.2008.03619.x","article-title":"Etanercept treatment in a hemodialysis patient with severe cyclosporine-resistant psoriasis and hepatitis C virus infection","volume":"47","author":"Cassano","year":"2008","journal-title":"Int. J. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s13730-019-00426-z","article-title":"Efficacy of Secukinumab for Plaque Psoriasis in a Patient on Hemodialysis","volume":"9","author":"Ikuma","year":"2020","journal-title":"CEN Case Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/1346-8138.12901","article-title":"Successful adalimumab treatment of a psoriasis vulgaris patient with hemodialysis for renal failure: A case report and a review of the previous reports on biologic treatments for psoriasis patients with hemodialysis for renal failure","volume":"42","author":"Kusakari","year":"2015","journal-title":"J. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1684\/ejd.2014.2401","article-title":"Good efficacy and tolerability of ustekinumab in a patient with severe psoriasis under haemodialysis","volume":"24","author":"Larquey","year":"2014","journal-title":"Eur. J. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/1346-8138.12989","article-title":"Successful treatment with ustekinumab of psoriasis vulgaris in a patient undergoing hemodialysis","volume":"43","author":"Nimmannitya","year":"2016","journal-title":"J. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e13348","DOI":"10.1111\/dth.13348","article-title":"Erythrodermic psoriasis in a dialyzed patient successfully treated with Secukinumab","volume":"33","author":"Pizzatti","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1007\/s10067-010-1485-4","article-title":"A case report of a psoriatic arthritis patient on hemodialysis treated with tumor necrosis factor blocking agent and a literature review","volume":"29","author":"Saougou","year":"2010","journal-title":"Clin. Rheumatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1111\/1346-8138.14649","article-title":"Case of psoriatic erythroderma induced by the discontinuation of the chronic use of topical steroid after dialysis initiation and successfully treated with secukinumab","volume":"46","author":"Shibata","year":"2019","journal-title":"J. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/1346-8138.12903","article-title":"Ustekinumab treatment in patients with psoriasis undergoing hemodialysis","volume":"42","author":"Umezawa","year":"2015","journal-title":"J. Dermatol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/8\/2250\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:27:08Z","timestamp":1760106428000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/8\/2250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,12]]},"references-count":35,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["jcm13082250"],"URL":"https:\/\/doi.org\/10.3390\/jcm13082250","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,12]]}}}